Type 1 diabetes mellitus treatment in seniors

1. Diamond Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabet Med 2006; 23: 857–866.

2. Patterson CC, Dahlquist GG, Gyürüs E, et al. EURODIAB study group: Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–2020: a multicentre prospective registration study. Lancet 2009; 373: 2027–2033.

3. International Diabetes Federation. Diabetes Atlas. Brussels, International Diabetes Federation 2011.

4. Schutt M, Fach EM, Seufert J, et al. DPV Initiative and the German BMBF Competence Network Diabetes Network: Multiple complications and frequent severe hypoglycaemia in ‘elderly’ and ‘old’ patients with type 1 diabetes. Diabet Med 2012; 29: 176–179.

5. JDRF Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the JDRF Continuous Glucose Monitoring trial. Diabetes Care 2010; 33: 17–22.

6. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238–245.

7. Microvascular and acute complications in IDDM patiens: the EURODIAB IDDM Complications study. Diabetologia 1994; 37: 278–285.

8. Braak EW, Appelman AM, van de Laak M, et al. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000; 23: 1467–1471.

9. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35: 1897–1901.

10. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552–1561.

11. Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ. Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Endocrinol Metab 2009; 297: 194–201.

12. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494–511.

13. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycaemia. Diabetes Care 1994; 17: 697–703.

14. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135–141.

15. Brierley EJ, Broughton DL, James OF, Alberti KG. Reduced awareness of hypoglycaemia in the elderly despite an intact counterregulatory response. Q J Med 1995; 88: 439–445.

16. Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513–1517.

17. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010; 39: 641–654.

18. Centers for Disease Control and Prevention. Vision health initiative. Dostupné na: www.cdc.gov. 6 July 2013

19. Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 2008; 149: 1–10.

20. Bainbridge KE, Hoffman HJ, Cowie CC. Risk factors for hearing impairment among U. S. adults with diabetes: National Health and Nutrition Examination Survey 1999–2004. Diabetes Care 2011; 34: 1540–1545.

21. Jaroslav Rybka. Zvláštnosti terapie diabetu u seniorů. Interní Med 2012; 14(8 a 9): 303–308.

22. Dhaliwal R, Weinstock RS. Management of type 1 diabetes in older adults. Diabetes Spectr 2014; 27(1): 9–20.

23. Pelikánová T, Bartoš V a kol. Praktická diabetologie. Maxdorf 2010.

24. Pena A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev 2016; 5(1): 69–75.

25. Haluzík M. Inzulin glargin 300 U/ml. Farmakoterapie 2015; 4: 474–479.

26. Adamíková A. Klinický význam bazálních inzulinů se zaměřením na Toujeo 300 U/ml. Vnitr Lek 2015; 61(11): 985–988.

27. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care [published online June 17, 2015].

28. Becker RHA, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab 2015; 17(3): 261–267.

29. Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Diabetes Obes Metab 2015;

30. Rosenstock J, et al. Basal insulin glargine (HOE 901) versus NPH insulin patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23(8): 1137–1142.

31. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U. S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23(5): 639–643.

32. DCCT (Diabetes Control and Complication Trial). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14).

33. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes Metab Res Rev 2014; 30:104–119.

34. Janíčková Žďárská D, Piťhová P, Kvapil M. Možnosti terapie inzulinem v roce 2015. Klin Farmakol Farm 2015; 29(1): 30–34.